LitAlert ~~ GeneLit.com

    • VPA and TSA Interrupt the Interplay between mutp53 and HSP70, Leading to CHK1 and RAD51 Down-Regulation and Sensitizing Pancreatic Cancer Cells to AZD2461 PARP Inhibitor.
    • Romeo MA, Gilardini Montani MS, Benedetti R, Arena A, D’Orazi G, Cirone M.
    • Int J Mol Sci. 2022 Feb 18;23(4):2268. doi: 10.3390/ijms23042268.

    • RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.
    • Miao C, Tsujino T, Takai T, Gui F, Tsutsumi T, Sztupinszki Z, Wang Z, Azuma H, Szallasi Z, Mouw KW, Zou L, Kibel AS, Jia L.
    • Sci Adv. 2022 Feb 18;8(7):eabl9794. doi: 10.1126/sciadv.abl9794. Epub 2022 Feb 18.

    • PARP Inhibitors Show Frontline Prostate Cancer Benefit; Conflicting Biomarker Data Raise Questions.
    • Hopkins C.
    • Precision Oncology News. Disease Areas. Cancer. 2022 Feb 17.
    • Conference report

    • Mass General, Lunaphore Technologies to Develop Test to Predict PARP Inhibitor Response.
    • [No author given]
    • Precision Oncology News. Disease Areas. Cancer. 2022 Feb 17.